January 30, 2014
Postmenopausal hormones containing estrogen may reduce glaucoma risk
Using postmenopausal hormones (PMH) containing estrogen may reduce a woman’s risk for primary open-angle glaucoma (POAG), a common form of the disease related to the build-up of pressure inside the eye, according to a study published by JAMA Ophthalmology and led by Joshua D. Stein, M.D., M.S., glaucoma specialist at the University of Michigan Kellogg Eye Center.
Some prior research has suggested that PMH use may be associated with modestly reduced intraocular pressure (IOP), which suggests PMH may decrease the risk for POAG, according to the study background.
Dr. Stein and colleagues examined claims data for women 50 years and older who were enrolled in a managed-care plan for at least four years and had at least two visits to an eye care provider from 2001 through 2009. They evaluated three different classes of PMH (estrogen, estrogen plus progesterone, or estrogen plus androgen) and the risk for POAG.
Of the 152,163 eligible enrollees, 2,925 (1.9 percent) developed POAG. Each additional month a woman used a PMH containing estrogen (E) alone was associated with a 0.4 percent reduced relative risk for POAG, according to the study results. There was no association between risk for POAG and use of estrogen plus progesterone or estrogen plus androgen.
“More research is needed to better elucidate the complex relationship between PMH use and glaucoma. Additional work should also further explore whether the risk for POAG is affected only by use of estrogen alone, or by use of any PMH class,” Dr. Stein concludes.
Study authors with U-M authors in bold:
Paula Anne Newman Casey, MD, MS; Nidhi Talwar, MA; Bin Nan, Ph.D.; David C. Musch PhD, MPH, Louis R. Pasquale, MD; Joshua D. Stein, MD, MS
JAMA Ophthalmol. Published online January 30, 2014. doi:10.1001/.jamaopthalmol.2013.7618.